Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
=== Nucleic acids === The convention for a nucleic acid sequence is to list the nucleotides as they occur from the 5' end to the 3' end of the polymer chain, where 5' and 3' refer to the numbering of carbons around the ribose ring which participate in forming the phosphate diester linkages of the chain. Such a sequence is called the primary structure of the biopolymer.
After 137Cs and 90Sr have decayed to low levels, the bulk of radioactivity from spent fuel come not from fission products but actinides, notably plutonium-239 (half-life 24 ka), plutonium-240 (6.56 ka), americium-241 (432 years), americium-243 (7.37 ka), curium-245 (8.50 ka), and curium-246 (4.73 ka). These can be recovered by nuclear reprocessing (either before or after most 137Cs and 90Sr decay) and fissioned, offering the possibility of greatly reducing waste radioactivity in the time scale of about 103 to 105 years. 239Pu is usable as fuel in existing thermal reactors, but some minor actinides like 241Am, as well as the non-fissile and less-fertile isotope plutonium-242, are better destroyed in fast reactors, accelerator-driven subcritical reactors, or fusion reactors. Americium-241 has some industrial applications and is used in smoke detectors and is thus often separated from waste as it fetches a price that makes such separation economic.
== Research == A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.
=== Detection in body fluids === Reviews that cover attention deficit hyperactivity disorder (ADHD) and phenethylamine indicate that several studies have found abnormally low urinary phenethylamine concentrations in ADHD individuals when compared with controls. In treatment-responsive individuals, amphetamine and methylphenidate greatly increase urinary phenethylamine concentration. An ADHD biomarker review also indicated that urinary phenethylamine levels could be a diagnostic biomarker for ADHD. Thirty minutes of moderate- to high-intensity physical exercise has been shown to induce an increase in urinary phenylacetic acid, the primary metabolite of phenethylamine. Two reviews noted a study where the mean 24 hour urinary phenylacetic acid concentration following just 30 minutes of intense exercise rose 77% above its base level; the reviews suggest that phenethylamine synthesis sharply increases during physical exercise during which it is rapidly metabolized due to its short half-life of roughly 30 seconds. In a resting state, phenethylamine is synthesized in catecholamine neurons from L-phenylalanine by aromatic amino acid decarboxylase at approximately the same rate as dopamine is produced. Monoamine oxidase deaminates primary and secondary amines that are free in the neuronal cytoplasm but not those bound in storage vesicles of the sympathetic neurone. Similarly, β-PEA would not be completely deaminated in the gut as it is a selective substrate for MAO-B, which is not primarily found in the gut.
==== In water ==== Cyanobacteria possess carboxysomes, which increase the concentration of CO2 around RuBisCO to increase the rate of photosynthesis. An enzyme, carbonic anhydrase, located within the carboxysome, releases CO2 from dissolved hydrocarbonate ions (HCO−3). Before the CO2 can diffuse out, RuBisCO concentrated within the carboxysome quickly sponges it up. HCO−3 ions are made from CO2 outside the cell by another carbonic anhydrase and are actively pumped into the cell by a membrane protein. They cannot cross the membrane as they are charged, and within the cytosol they turn back into CO2 very slowly without the help of carbonic anhydrase. This causes the HCO−3 ions to accumulate within the cell from where they diffuse into the carboxysomes. Pyrenoids in algae and hornworts also act to concentrate CO2 around RuBisCO.
Sources: en.wikipedia.org
Effects of growth hormone on the tissues of the body can generally be described as anabolic (building up). Like most other peptide hormones, GH acts by interacting with a specific receptor on the surface of cells. Increased height during childhood is the most widely known effect of GH. Height appears to be stimulated by at least two mechanisms:
==== Films in which Jung is a character in the narrative ==== 2002 saw the release of an Italian film about Jung and Spielrein, The Soul Keeper (Prendimi l'Anima) directed by Roberto Faenza. It used English dialogue and English actors, but was never formally released in the United States. Emilia Fox played Sabina Spielrein and Iain Glen was Carl Gustav Jung. A Dangerous Method, a 2011 film directed by David Cronenberg, is a fictional dramatisation of the lives of Freud, Jung, and Sabina Spielrein between 1904 and 1913. Spielrein is the Russian woman who became Jung's lover and student and, later, an analyst herself. Michael Fassbender plays Carl Jung. The film is based on the stage play The Talking Cure by Christopher Hampton, which was in turn based on the 1993 non-fiction book by John Kerr, A Most Dangerous Method: The Story of Jung, Freud, and Sabina Spielrein. In the online animated series, Super Science Friends, Jung, voiced by Tom Park, is featured as one of the recurrent antagonists against Sigmund Freud. Soul, a 2020 Pixar film written by Pete Docter, Mike Jones and Kemp Powers, includes brief appearances of Jung as an ethereal cartoon character, "Soul Carl Jung". Jeff Lillico portrays Jung in episode 13 of season 15 "Murdoch on the Couch" (10 January 2022) of the Canadian television period detective series Murdoch Mysteries.
== See also == Timeline of computing 2020–present Pandemic prevention § Surveillance and mapping COVID-19 surveillance Teamwork Open-source software development Citizen science § COVID-19 pandemic Information management COVID-19 pandemic#Information dissemination Open-source ventilator Bioinformatics Impact of the COVID-19 pandemic on science and technology#Computing and machine learning research and citizen science Public health mitigation of COVID-19 § Information technology Technology policy
It provided a feeling of freedom to college students who could not express their political opinions openly in 1970s. As the competition amongst dabangs increased in the 1980s, they decorated themselves with distinctive items, such as pink lights and indoor waterfalls, to survive in the increasingly crowded marketplace. At that time, dabangs underwent huge changes in their atmosphere and menu. For example, dark dabangs with dividers to block others' views changed into the ones with bright and cozier atmospheres. This new type of coffee shop, which called themselves cafés to distinguish themselves from old style dabangs, began to focus on different kinds of coffee instead of selling traditional teas and sodas. In the 1990s, people thought that consumption had a style and preferred cafés with a neater interior design and professionalism in coffee. There was a huge shift in Korean café culture's history in 1999 when Starbucks, the first foreign franchise coffee shop in Korea, was established in Sinchon, Seoul. Starbucks introduced Korea to a new café culture, such as take-out and self-service system without good-looking waitresses and staying at a café alone reading a book or doing homework. Since then, more foreign franchise coffee shops entered the market with a greater variety of coffee and atmosphere, and more local franchise cafés and small private-owned cafés appeared with their unique features.
Sources: en.wikipedia.org
Physical presence may be required for women who are in relationships for the testosterone–partner interaction, where same-city partnered women have lower testosterone levels than long-distance partnered women.
== Medical uses == Diclofenac is used to treat pain related to arthritis, dysmenorrhea, rheumatic diseases and other inflammatory disorders, kidney stones and gallstones. An additional indication is the treatment of acute migraines. Diclofenac is used to treat mild to moderate postoperative or post-traumatic pain, in particular when inflammation is also present. Diclofenac ophthalmic is indicated for the treatment of postoperative inflammation in people who have undergone cataract extraction and for the temporary relief of pain and photophobia in people undergoing corneal refractive surgery. Diclofenac may also help with actinic keratosis and with acute pain caused by minor strains, sprains and contusions. In many countries, eye drops are sold to treat acute and chronic nonbacterial inflammation of the anterior part of the eyes (such as postoperative states). The eye drops have also been used to manage pain for traumatic corneal abrasion. Diclofenac is often used to treat chronic pain associated with cancer, especially if inflammation is present.
=== Hyperglycemia hyperosmolar state (HHS) === hyperosmolar non-ketotic state (HONK) or Hyperglycemia hyperosmolar state (HHS) is an acute complication sharing many symptoms with DKA, but an entirely different origin and different treatment. Oppositely, the prevalence of HHS is common in individuals with T2D. Furthermore, it showcases approximately ten times greater mortality rate than the observed in DKA. Both DKA and HHS occur when insulin becomes less effective, either due to a shortage of insulin secretion ( as in DKA), or lack of proper insulin action (as in HHS). For a person with very high blood glucose levels (usually considered to be above 30 mmol/L (600 mg/dL), that will result in osmotic diuresis, water is osmotically drawn out of cells into the blood and the kidneys eventually begin to dump glucose into the urine. This results in a loss of water (which contains electrolytes and glucose) that will increase blood osmolarity. If the fluid is not replaced, by mouth or intravenously, will ultimately result in dehydration (which in HHS typically becomes worse than DKA). Also causes electrolyte imbalances which are always dangerous. A decline in consciousness levels is primarily attributed to an increase in plasma osmolality. Lethargy may ultimately progress to a coma which is more common in T2D than T1D. HHS, unlike DKA, does not result in significant ketosis and acidosis, or there may be only a very minimal. This is because the presence of a small quantity of insulin suppresses the release of counterregulatory hormones and limits the production of ketones.
=== Approaches to improve thermostability of proteins === Protein engineering can be used to enhance the thermostability of proteins. A number of site-directed and random mutagenesis techniques, in addition to directed evolution, have been used to increase the thermostability of target proteins. Comparative methods have been used to increase the stability of mesophilic proteins based on comparison to thermophilic homologs. Additionally, analysis of the protein unfolding by molecular dynamics can be used to understand the process of unfolding and then design stabilizing mutations. Rational protein engineering for increasing protein thermostability includes mutations which truncate loops, increase salt bridges or hydrogen bonds, introduced disulfide bonds. In addition, ligand binding can increase the stability of the protein, particularly when purified. There are various different forces that allow for the thermostability of a particular protein. These forces include hydrophobic interactions, electrostatic interactions, and the presence of disulfide bonds. The overall amount of hydrophobicity present in a particular protein is responsible for its thermostability. Another type of force that is responsible for thermostability of a protein is the electrostatic interactions between molecules. These interactions include salt bridges and hydrogen bonds. Salt bridges are unaffected by high temperatures, therefore, are necessary for protein and enzyme stability. A third force used to increase thermostability in proteins and enzymes is the presence of disulfide bonds.
In June 2025, Compass Pathways, which is developing psilocybin for treatment-resistant depression, announced the results of a Phase III clinical trial of single-dose 25 mg psilocybin (COMP360) versus placebo. Psilocybin met the primary endpoint of a significant reduction in depressive scores on the Montgomery-Asberg Depression Rating Scale (MADRS) relative to placebo. At the 6-week point, there was a 3.6-point reduction in depressive symptoms on the scale compared to placebo. The degree of improvement over placebo was small and below expectations: a minimum advantage of at least 5 points over placebo had been expected and deemed acceptable, for instance by the company's investors. Compass Pathways' second Phase 3 trial of COMP360 met its primary endpoint, but the effect size was modest and the added benefit of a second dose was unclear. Questions remain about the durability of psilocybin's antidepressant effects, the scalability of its treatment delivery, and regulatory uncertainty. Most clinical trials of psilocybin for depression have had financial conflicts of interest and significant risk of bias. Small sample sizes were common in the trials. The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of psychedelics like psilocybin for treatment of psychiatric disorders.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.